https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-07 / Biomed Res Int 2017;2017:5618174
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-07 / Biomed Res Int 2017;2017:56181742017-06-07 00:00:002017-06-07 00:00:00Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-01 / Clin Adv Hematol Oncol 2017 Jun;15(6):466-477
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-01 / Clin Adv Hematol Oncol 2017 Jun;15(6):466-4772017-06-01 00:00:002017-06-01 00:00:00Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-3512017-03-21 00:00:002017-03-21 00:00:00Current status of clinical trials assessing oncolytic virus therapy for urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-01 / Urol Oncol 2016 12;34(12):538-547
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-01 / Urol Oncol 2016 12;34(12):538-5472016-12-01 00:00:002016-12-01 00:00:00Emerging role of immunotherapy in urothelial carcinoma-Advanced disease
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-25 / J Urol 2017 01;197(1):14-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-25 / J Urol 2017 01;197(1):14-222016-07-25 00:00:002016-07-25 00:00:00Immunotherapy for the Treatment of Urothelial Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-03 / BJU Int. 2016 10;118(4):506-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-03 / BJU Int. 2016 10;118(4):506-142016-06-03 00:00:002019-02-15 08:52:00Recent advances in immuno-oncology and its application to urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-02-09 / Ther Adv Urol 2016 Jun;8(3):203-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-02-09 / Ther Adv Urol 2016 Jun;8(3):203-142016-02-09 00:00:002016-02-09 00:00:00Novel immunotherapeutic approaches to the treatment of urothelial carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-602012-08-09 00:00:002019-02-15 08:53:37Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-01 / BJU Int. 2005 Oct;96(5):728-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-01 / BJU Int. 2005 Oct;96(5):728-352005-10-01 00:00:002005-10-01 00:00:00The immunotherapy of prostate and bladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Vopr Onkol 2005;51(6):685-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Vopr Onkol 2005;51(6):685-82005-01-01 00:00:002019-02-15 08:53:38[Combined radiotherapy and endovascular x-ray therapy for invasive cancer of the urinary bladder]
